Pfizer to pay $142.1 million over off-label marketing of Neurontin
Global drugs behemoth Pfizer (NYSE: PFE) has been ordered to pay a total of $142.1 million in damages for violating federal laws in the off-label marketing of its epilepsy drug Neurontin (gabapentin), reports Bloomberg. The company plans to appeal the verdict, said the news service.
The case came as a result of the Kaiser Foundation Health Plan and Kaiser Foundation Hospitals contending - in a month long trial last year - that Pfizer illegally promoted Neurontin for unapproved uses (The Pharma Letter March 26, 2010).
Judge Patti Saris of US District Court in Boston upheld last year’s jury finding that the Kaiser Foundation and Kaiser Foundation Hospitals deserved the award over their claims that Pfizer illegally promoted Neurontin for unapproved uses.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze